2. April 2016 von

Victoza® (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment

Novo Nordisk A/S: Boston (ots/PRNewswire) – For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #689-P Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in …

Comments are closed.